Novo Nordisk to boost US diabetes sales force by 60%

Danish drugmaker Novo Nordisk announced plans to boost the size of its US diabetes care sales force by 60%, or 700 reps, before mid-2007. Novo Nordisk controls approximately 40% of the US insulin market, which has grown increasingly competitive over the past two years following the launches of Lilly and Amylin’s GLP-1 inhibitor Byetta, Pfizer’s Exubera inhaled insulin and Merck’s DPP-4 inhibitor Januvia. Novo Nordisk said the goal of its field force expansion is to further support its currently marketed insulin analogs—Levemir, NovoLog Mix 70/30 and NovoLog—and gear up for the planned 2009 launch of its Liraglutide diabetes treatment. Analysts said the Novo sales force increase is a defensive move to help the company compete with Januvia, Exubera and Novartis’ yet-to-be approved Galvus. Poul la Cour, an analyst with Carnegie Bank, told United Press International that other companies won’t raise their sales force levels as a response. “That’s because their competitors…already have more sales reps than Novo. Eli Lilly might increase to support Byetta…But so far, that launch has been incredible, so they'll only increase if there's a slow-down.”
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.